For in vitro diagnostic use. Others Elecsys HSV-2 IgG IVD Elecsys® HSV-2 IgG CPS_000485 08948909190 HSV-2 IgG Elecsys E2G 100 V2 Elecsys HSV-2 IgG 07613336170687 Reagents, kits 100 tests cobas e 411/601/602 true 05572193190 HSV-2 IgG Elecsys cobas e 100 Elecsys HSV-2 IgG 04015630927470 Reagents, kits 100 tests cobas e 411/601/602 true 08948887160 HSV-2 IgG Elecsys cobas e 100 V2 Elecsys HSV-2 IgG 07613336170694 Reagents, kits 100 tests cobas e 411/601/602 true 05572193160 HSV-2 IgG Elecsys cobas e 100 Elecsys HSV-2 IgG 04015630939053 Reagents, kits 100 tests cobas e 411/601/602 true 07027508190 HSV-2 IgG Elecsys E2G 100 Elecsys HSV-2 IgG 04015630940448 Reagents, kits 100 tests cobas e 402/801 true 08948887190 HSV-2 IgG Elecsys cobas e 100 V2 Elecsys HSV-2 IgG 07613336170670 Reagents, kits 100 tests cobas e 411/601/602 true 08948909501 Elecsys HSV-2 IgG en 1 FF00000005E0820E FF00000005E0820E 08948909190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended UseImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and lithium‑heparin plasma, K2‑EDTA plasma, and K3‑EDTA plasma. The test is intended for sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV‑2 infection. The test results may not determine the state of active lesions or associated disease manifestations, particularly for primary infection. The predictive value of positive and negative results depends on the population’s prevalence and the pretest likelihood of HSV‑2. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.This test is not FDA‑cleared for screening blood or plasma donors. The performance of this assay has not been established for use in a pediatric population, neonates, or immunocompromised patients, or for use at point‑of‑care facilities. en 08948909500 Elecsys HSV-2 IgG en 2 FF00000005ED580E FF00000004B4B60E 08948909190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and plasma. The test is intended for use as an aid in the assessment of immune status and as an aid in the diagnosis of HSV infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08948909500 Elecsys HSV-2 IgG en 1 FF00000004B4B60E FF00000004B4B50E 08948909190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and plasma. The test is intended for use as an aid in the assessment of immune status and as an aid in the diagnosis of HSV infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_05572193190 Elecsys HSV-2 IgG en 8 FF0000000440CA0E FF000000003A650E 05572193190 618 cobas e 411 2325 cobas e 602 623 MODULAR ANALYTICS E-MODULE 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and plasma. The test is intended for use as an aid in the assessment of immune status and as an aid in the diagnosis of HSV infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 08948887501 Elecsys HSV-2 IgG en 1 FF00000005DDE20E FF00000005DDE20E 08948887160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and lithium‑heparin plasma, K2‑EDTA plasma, and K3‑EDTA plasma. The test is intended for sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV‑2 infection. The test results may not determine the state of active lesions or associated disease manifestations, particularly for primary infection. The predictive value of positive and negative results depends on the population’s prevalence and the pretest likelihood of HSV‑2. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.This test is not FDA‑cleared for screening blood or plasma donors.The performance of this assay has not been established for use in a pediatric population, neonates, immunocompromised patients, or for use at point‑of‑care facilities. en ms_05572193160_USA Elecsys HSV-2 IgG en 5 FF0000000280A70E FF0000000059B50E 05572193160 618 cobas e 411 2325 cobas e 602 623 MODULAR ANALYTICS E-MODULE 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended UseImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and lithium‑heparin plasma, K2‑EDTA plasma, and K3‑EDTA plasma. The test is intended for sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV‑2 infection. The predictive value of positive or negative results depends on the population’s prevalence and the pretest likelihood of HSV‑2. The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers.This test is not FDA‑cleared for screening blood or plasma donors. The performance of this assay has not been established for use in a pediatric population, neonates, or immunocompromised patients or for use at point‑of‑care facilities. en 07027508501 Elecsys HSV-2 IgG en 2 FF00000005C8700E FF00000001EF840E 07027508190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended UseImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and lithium‑heparin plasma, K2‑EDTA plasma, and K3‑EDTA plasma. The test is intended for sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV‑2 infection. The predictive value of positive or negative results depends on the population’s prevalence and the pretest likelihood of HSV‑2. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.This test is not FDA‑cleared for screening blood or plasma donors. The performance of this assay has not been established for use in a pediatric population, neonates, or immunocompromised patients or for use at point‑of‑care facilities. en 07027508500 Elecsys HSV-2 IgG en 4 FF000000049B510E FF0000000456530E 07027508190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative determination of IgG class antibodies to HSV‑2 in human serum and plasma. The test is intended for use as an aid in the assessment of immune status and as an aid in the diagnosis of HSV infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en